Arzanya and leadXpro AG announce a partnership to explore the potential for combining their specific technology platforms and knowledge to discover macrocyclic ligands binding to membrane protein drug targets.
We are thrilled to partner with leadXpro, a global leader in GPCR research, to advance our platform and unlock the potential of macrocyclic peptides against challenging pharmaceutical targets.
Alessandro Angelini, Arzanya
The collaboration combines Arzanya’s high-throughput yeast display screening platform for the selection of peptide macrocycles with leadXpro’s expertise in membrane protein generation, structure determination and the application of biophysical methods to investigate the potential for discovering novel ligands against challenging membrane protein drug targets.
We’re excited to complement our capabilities with Arzanya’s novel yeast display technology for macrocyclic peptide discovery and expand the druggable target space.
Michael Hennig, leadXpro
leadxpro specializes in structure-based drug discovery for membrane proteins. We combine membrane protein science from gene to biophysical methods and structural biology using cryo-EM and X-ray methods. So far, we have established over 105 drug targets accelerating drug discovery efforts worldwide.
Arzanya is an Italian biotechnology start-up and spin-off from Ca’ Foscari University of Venice that operates in the health and biomedicine sector.
